Web21. mar 2024. · Importantly, somatic copy number variant (CNV) analysis revealed MAP2K4 copy-number gain (i.e., gene amplification) in approximately 30% of uLMS, suggesting that MAP2K4 inhibitors may represent novel, potentially effective targeted agents against this rare and difficult to treat disease. WebDiscovery and classification. MAP4K4 is categorized under the mammalian sterile 20 protein (Ste20p) kinase family due to its shared homology with the Ste20p kinase found in …

US20240153861A1 THERAPEUTIC AND DIAGNOSTIC METHODS …

Web01. avg 2014. · MAP2K4 gene amplification has been reported in some sarcomas including a minority of leiomyosarcomas using microarray comparative genomic hybridization [16], … WebDNA Amplification and Sequencing Genomic DNA samples (40 ng per reaction) were screened for homozygous deletions utilizing PCR analysis as previously described (Caldas et al., 1994; Schutte et al., 1995). The MAP2K4 primers were identical to those described previously (Teng et al., 1997). Loss of heterozygosity (LOH) was determined using four ... button hover left to right

Uterine leiomyosarcomas harboring MAP2K4 gene amplification …

WebMAP3K13 Amplification is present in 0.60% of AACR GENIE cases, with squamous cell lung carcinoma, breast invasive ductal carcinoma, high grade ovarian serous adenocarcinoma, anal squamous cell carcinoma, and small cell lung carcinoma having the greatest prevalence [ 4 ]. Top Disease Cases with MAP3K13 Amplification References 1. WebMAP2K4 encodes a dual-specificity kinase (mitogen-activated protein kinase kinase 4, or MKK4) that is mutated in a variety of human malignancies, but the biochemical properties of the mutant kinases and their roles in tumorigenesis have not been fully elucidated. cedar street armory mn